John H. Johnson

Former Chairman and CEO, Dendreon Corporation


A member of the W2O Board of Directors since April 2017, John has more than 30 years of experience leading and growing global biopharmaceutical organizations. He has served as Chairman of the Board of Strongbridge Biopharma since March 2015 and currently serves as Chief Executive Officer and Director of Melinta Therapeutics, having served as interim Chief Executive Officer from October 2018 to February 2019. In August 2017, Melinta merged with Cempra, Inc. Prior to the merger, John had been on the board of Cempra since June 2009.

John is also on the board of AVEO Oncology, the Histogenics Corporation, and Portola Pharmaceuticals and served on the board at Sucampo Pharmaceuticals until its August 2017 merger with Mallinckrodt. Other organizations he has led in his career include Dendreon, Johnson & Johnson, Eli Lilly & Company, ImClone, and Pfizer, Inc.

In addition to John’s extensive leadership experience and commercial expertise within biopharmaceutical companies, he has served on several industry boards—the Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Innovation Organization (BIO), and BioNJ.